Cyclopropyl-cyclobutyl-amin | 823-13-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Cyclopropyl-cyclobutyl-amin
• 英文别名: N-cyclopropylcyclobutanamine
• CAS: 823-13-2
• 化学式: C₇H₁₃N
• 分子量: 111.187
• InChiKey: DJLMNGVZYQJHPJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  8
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• NUCLEATING AGENT, SYNTHETIC-RESIN COMPOSITION CONTAINING SAME, AND MOLDED OBJECT THEREOF
  申请人：ADEKA CORPORATION

  公开号：US20210395209A1

  公开（公告）日：2021-12-23

  Provided are: a novel nucleating agent capable of imparting excellent transparency to synthetic resins; a synthetic resin composition containing the same; and a molded object of the synthetic resin composition. The nucleating agent contains at least one triazine compound represented by Formula (1), wherein Ar 1 , Ar 2 and Ar 3 each independently represent an unsubstituted phenyl group or a substituted phenyl group. In Formula (1), for example, the number of substituents of the substituted phenyl group is preferably 1, and Ar 1 , Ar 2 and Ar 3 are preferably all different groups.

  提供了一种新型成核剂，能够为合成树脂赋予卓越的透明度；一种含有该成核剂的合成树脂组合物；以及该合成树脂组合物的成型物。该成核剂包含至少一种由式（1）表示的三嗪化合物，其中Ar1、Ar2和Ar3各自独立地表示未取代苯基或取代苯基。在式（1）中，例如，取代苯基的取代基数目最好为1，且Ar1、Ar2和Ar3最好都是不同的基团。
• Novel isoindole derivatives
  申请人：Banyu Pharmaceutical Co., Ltd.

  公开号：US20040053923A1

  公开（公告）日：2004-03-18

  This invention relates to compounds represented by the general formula [I] 1 wherein, R represents an azido group, etc., R 1 and R 2 are the same or different and represent hydrogen atoms, etc., R 3 and R 4 are the same or different and represent hydrogen atoms, etc., X 1 represents an oxygen atom, etc., X 2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及由一般式[I]1表示的化合物，其中，R代表叠氮基等，R1和R2相同或不同，代表氢原子等，R3和R4相同或不同，代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表紧缩芳基基团等，或其药学上可接受的盐，其制备方法以及作为治疗糖尿病的药物、预防糖尿病慢性并发症的预防剂或抗肥胖药物的有效成分，包含该化合物或其药学上可接受的盐。
• Tissue Factor Production Inhibitor
  申请人：Terasaka Naoki

  公开号：US20080255111A1

  公开（公告）日：2008-10-16

  A medicament which has an activity of inhibiting production of tissue factor and comprises an LXR ligand as an active ingredient; and a medicament for treatment and/or prophylaxis of vascular restenosis following angioplasty, endarterectomy, percutaneous transluminal coronary angioplasty (PTCA) or stent implantation, or treatment and/or prophylaxis of blood coagulation diseases, diseases induced by platelet aggregation including stable or unstable angina pectoris, cardiovascular and cerebrovascular diseases including thromboembolism formation diseases accompanying diabetes, rethrombosis following thrombolysis, cerebral ischemic attack, infarction, stroke, ischemia-derived dementia, peripheral artery disease, thromboembolism formation diseases during use of an aorta-coronary artery bypass, glomerulosclerosis, renal embolism, tumor or cancer metastasis, which comprises an LXR ligand as an active ingredient.

  一种药物，具有抑制组织因子产生活性，包括LXR配体作为活性成分;以及用于治疗和/或预防血管再狭窄的药物，包括血管成形术，动脉内膜切除术，经皮冠状动脉成形术（PTCA）或支架植入术后的治疗和/或预防，或治疗和/或预防血液凝固疾病，包括稳定或不稳定的心绞痛，心血管和脑血管疾病，包括伴随糖尿病的血栓栓塞形成疾病，溶栓后再栓塞，脑缺血发作，梗塞，中风，缺血性痴呆，周围动脉疾病，主动脉冠状动脉旁路使用期间的血栓栓塞形成疾病，肾小球硬化，肾脏栓塞，肿瘤或癌症转移，其中包括LXR配体作为活性成分。
• Benzene Compound Having 2 or More Substituents
  申请人：Tamaki Kazuhiko

  公开号：US20080004301A1

  公开（公告）日：2008-01-03

  A superior LXR modulator is provided. A compound represented by the general formula (I): [wherein R 1 : —COR 9 (wherein R 9 : alkyl, optionally substituted alkoxy or optionally substituted amino); R 2 : H, OH, alkoxy, optionally substituted amino, etc.; R 3 : H, optionally substituted alkyl, cycloalkyl, optionally substituted alkoxy, optionally substituted amino, halogeno, etc.; R 4 and R 5 : H, optionally substituted alkyl, halogeno, etc.; R 6 and R 7 : H, alkyl; R 8 : —X 2 R 10 [wherein R 10 : —COR 11 (wherein R 11 : OH, optionally substituted alkoxy, optionally substituted amino, etc.), —SO 2 R 12 (wherein R 12 : optionally substituted alkyl, optionally substituted amino, etc.), tetrazol-5-yl, etc.; X 2 : single bond, optionally substituted alkylene, etc.]; X 1 : —NH—, —O—, —S—, etc.; Y 1 : optionally substituted phenyl, optionally substituted 5- to 6-membered aromatic heterocyclyl; Y 2 : optionally substituted aryl, optionally substituted heterocyclyl, etc.] and the like is provided.

  提供了一种优越的LXR调节剂。化合物的一般式(I)如下：[其中R1：-COR9（其中R9：烷基，可选地取代的烷氧基或可选地取代的氨基）；R2：H，OH，烷氧基，可选地取代的氨基等；R3：H，可选地取代的烷基，环烷基，可选地取代的烷氧基，可选地取代的氨基，卤素等；R4和R5：H，可选地取代的烷基，卤素等；R6和R7：H，烷基；R8：-X2R10 [其中R10：-COR11（其中R11：OH，可选地取代的烷氧基，可选地取代的氨基等），-SO2R12（其中R12：可选地取代的烷基，可选地取代的氨基等），四唑-5-基等；X2：单键，可选地取代的烷基等]；X1：-NH-，-O-，-S-等；Y1：可选地取代的苯基，可选地取代的5-至6-成员芳香杂环基；Y2：可选地取代的芳基，可选地取代的杂环基等]。
• NOVEL ISOINDOLE DERIVATIVES
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP1207161A1

  公开（公告）日：2002-05-22

  This invention relates to compounds represented by the general formula [I] wherein, R represents an azido group, etc., R1 and R2 are the same or different and represent hydrogen atoms, etc., R3 and R4 are the same or different and represent hydrogen atoms, etc., X1 represents an oxygen atom, etc., X2 represents an oxygen atom, etc., Y represents an oxygen atom, etc., and Z represents a condensed aryl group, etc., or a pharmaceutically acceptable salt thereof, preparation processes thereof, and an agent for treating diabetes, a prophylactic agent for chronic complications of diabetes or a drug against obesity, containing, as an effective ingredient, the compound or the pharmaceutically acceptable salt thereof.

  本发明涉及通式[I]所代表的化合物 其中，R代表叠氮基等，R1和R2相同或不同且代表氢原子等，R3和R4相同或不同且代表氢原子等，X1代表氧原子等，X2代表氧原子等，Y代表氧原子等，Z代表缩合芳基等、或其药学上可接受的盐、其制备工艺，以及含有该化合物或其药学上可接受的盐作为有效成分的治疗糖尿病的药物、治疗糖尿病慢性并发症的预防药物或防治肥胖症的药物。